Revised mTOR Deal With Merck Gives Ariad Time
Ariad gives up co-development and commercialization rights to ridaforolimus but gets $69 million to fund operations.
Ariad gives up co-development and commercialization rights to ridaforolimus but gets $69 million to fund operations.